Milan R. Amin

Milan R. Amin

Auto-generated profile, based on publicly available information

Milan R. Amin

NYU Langone Medical Center

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2000 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Open access
JKJames A. Koufman
James A. Koufman
MAMilan R. Amin
Milan R. Amin
MPMarguerite Panetti
Marguerite Panetti
OBJECTIVES: The goal was to estimate the prevalence of laryngopharyngeal reflux (LPR) in patients with laryngeal and voice disorders.STUDY DESIGN AND SETTING: This was a prospective study of 113 unselected, new patients with laryngeal and voice disorders. Patients completed an extensive medical history form including a reflux symptom profile. A comprehensive otolaryngologic examination was performed with photographic transnasal fiberoptic laryngoscopy. Patients with both symptoms and findings of LPR (78/133, 69%) underwent ambulatory 24‐hour double‐probe pH monitoring.RESULTS: Seventy‐three percent (57/78) of patients undergoing pH testing had abnormal studies. Thus 50% (57/113) of the entire the study population had pH‐documented reflux. Of the diagnostic sub‐groups studied, the highest incidence of reflux was found in patients with vocal cord neoplastic lesions (88%) and patients with muscle tension dysphonias (70%). LPR was infrequently found in patients with neuromuscular disorders.CONCLUSION: LPR occurs in at least 50% of all patients at our center with laryngeal and voice disorders at presentation.

6 June 2020 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Open access
PDF file
CPCesare Piazza
Cesare Piazza
MFmarta filauro
marta filauro
FDFrederik G. Dikkers
Frederik G. Dikkers
SNS. A. Reza Nouraei
S. A. Reza Nouraei
KSKishore Sandu
Kishore Sandu
GPGiorgio Peretti
Giorgio Peretti
Introduction The novel Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2, may need intensive care unit (ICU) admission in up to 12% of all positive cases for massive interstitial pneumonia, with possible long-term endotracheal intubation for mechanical ventilation and subsequent tracheostomy. The most common airway-related complications of such ICU maneuvers are laryngotracheal granulomas, webs, stenosis, malacia and, less commonly, tracheal necrosis with tracheo-esophageal or tracheo-arterial fistulae. Materials and methods This paper gathers the opinions of experts of the Laryngotracheal Stenosis Committee of the European Laryngological Society, with the aim of alerting the medical community about the possible rise in number of COVID-19-related laryngotracheal stenosis (LTS), and the aspiration of paving the way to a more rationale concentration of these cases within referral specialist airway centers. Results A range of prevention strategies, diagnostic work-up, and therapeutic approaches are reported and framed within the COVID-19 pandemic context. Conclusions One of the most important roles of otolaryngologists when encountering airway-related signs and symptoms in patients with previous ICU hospitalization for COVID-19 is to maintain a high level of suspicion for LTS development, and share it with colleagues and other health care professionals. Such a condition requires specific expertise and should be comprehensively managed in tertiary referral centers.

8 December 2009 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
LSLucian Sulica
Lucian Sulica
CRClark A. Rosen
Clark A. Rosen
GPGregory N. Postma
Gregory N. Postma
BSBlake Simpson
Blake Simpson
MAMilan Amin
Milan Amin
AMAlbert Merati
Albert Merati

1 January 2020 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
AGAlexander Gelbard
Alexander Gelbard
CACatherine Anderson
Catherine Anderson
LBLynne D. Berry
Lynne D. Berry
MAMilan R. Amin
Milan R. Amin
MBMichael S. Benninger
Michael S. Benninger
DFDavid O. Francis
David O. Francis
The paradox of rare diseases is that any single diagnosis affects a small number of individuals, but 6% to 8% of the world population is afflicted.1 This fact renders rare diseases both difficult to study and a significant public health concern. Even basic epidemiologic studies of rare diseases are challenging given the heterogeneous, progressive clinical course of the rare disease and the geographic dispersion of patients.2 Geographic distribution requires an extensive recruitment and monitoring infrastructure, dramatically increasing the cost and time required for participant accrual. These barriers, coupled with small markets, reduce incentives for the pharmaceutical industry and funders to support rare disease research,3 constrain evidence, and result in clinical practice variation and inconsistent patient outcomes.

24 October 2009 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
CRClark A. Rosen
Clark A. Rosen
MAMilan R. Amin
Milan R. Amin
LSLucian Sulica
Lucian Sulica
CSC. Blake Simpson
C. Blake Simpson
AMAlbert L. Merati
Albert L. Merati
GPGregory N. Postma
Gregory N. Postma

1 July 2001 in American Journal of Otolaryngology
Verified
Journal Article
Closed access
MAMilan R. Amin
Milan R. Amin
JKJames A. Koufman
James A. Koufman